

Agents for Prostate Cancer - Essential Formulary

PRIOR REVIEW/CERTIFICATION FAXBACK FORM

INCOMPLETE FORMS MAY DELAY PROCESSING

ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

P	PRESCRIBER NAME	PRESCRIBER NPI [REQUIRED]	Blue Cross NC PROV ID # / TAX I	D [out of state	e]
С	CONTACT PERSON	PRESCRIBER PHONE	PRESCRIBER FAX	(
P	PRESCRIBER ADDRESS	CITY STATE	ZIP		
P	PATIENT NAME	Blue Cross NC ID	DATE OF BIRTH	GENDER	
				M F	
Di	iagnosis Code:				
PΙ	ease select the requested med	ication and answer the following	questions:		
	□ Erleada □ brand Zytiga 250mg □ brand Zytiga 500mg	☐ Nubeqa☐ generic abiraterone 250r☐ generic abiraterone 500r		i	
1.	Is the patient 18 years of age o	r older?		Yes	□ No
2.	Is the patient managed by or in	consultation with an oncologist or u	urologist?	□ Yes	□ No
3.	Is the request for brand Zytiga,	generic abiraterone or Abirtega?		Yes	□ No
		lowing questions: a diagnosis of metastatic castrationa a diagnosis of metastatic, high-risk o			□ No
	cancer?		······································	Yes	□ No
	d. Will the patient be using	requested medication in combination generic abiraterone 250mg tablets	s or Abirtega 250mg		□No
	i. If NO, please ex	xplain why using generic 250mg tab	olets or Abirtega 250mg	□ Yes —	□ No
4.	Is the request for Yonsa?			 □ Yes	 □ No
	If YES, please answer the following				- N
		a diagnosis of metastatic castration- g methylprednisolone in combination			□ No □ No
5.	·				□ No
	If YES, please answer the following	lowing questions:			
	•	a diagnosis of castration-resistant p a diagnosis of metastatic castration-			□ No □ No
	c. Does the patient have a	a diagnosis of non-metastatic castra	ation-sensitive prostate canc	er,	
	with biochemical recurr	ence at high risk for metastasis?		□ Yes	□ No
	continued on page	2; please complete and sign page 2	2 for prior authorization requ	est	

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.

DATE: March 2025 Page 1



Agents for Prostate Cancer (continued) Essential Formulary

6.	Is the request for Nubeqa?	□ Yes	□ No						
	IF YES, please answer the following questions:								
	a. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer?		□ No						
	b. Does the patient have a diagnosis of metastatic hormone-sensitive prostate cancer?		□ No						
	i. IF YES, will Nubeqa be used in combination with docetaxel?	□ Yes	□ No						
7.	Is the request for Erleada?	Yes	□ No						
	If YES, please answer the following questions:								
	Does the patient have a diagnosis of non-metastatic castration-resistant prostate	□ Voo	□ No						
	cancer?b. Does the patient have a diagnosis of metastatic castration-sensitive prostate cancer?		□ No □ No						
	c. Will the patient be concurrently receiving a gonadotropin-releasing hormone (GnRH)	⊔ 103	LI INC						
	analog?	□ Yes	□ No						
	d. Has the patient undergone a bilateral orchiectomy?		□ No						
O									
ŏ.	Will the patient be using the requested medication for indications outside of FDA labeling? IF YES, please indicate condition:		□ No						
	IF YES, please indicate condition: Medical records and references / evidence must be provided in order for this request to be pr	rocessed.							
9.			□ No						
٥.	a. IF YES , is the patient taking the requested medication for a cancer diagnosis?	□ Yes							
	i. IF YES , will the patient be using the generic version of this medication?								
	ii. IF NO , please provide rationale for the use of the brand name medication and SUB								
	SUPPORTING MEDICAL RECORD DOCUMENTATION:		<u>_</u>						
			_						
10.	. Is the requested medication a BRAND medication with an FDA approved AB rated generic								
	equivalent?	□ Yes	□ No						
	a. If YES, has the patient tried the generic product of the requested medication?		□ No						
	If YES, please answer the following questions and SUBMIT MEDICAL RECORD DOCU		□ No □ No □ No □ No □ No ON : □ No						
	i. Did the patient have a life-threatening side effect to the generic medication that requ								
	medical intervention that is not anticipated with the brand product?	□ Yes	□ No						
	ii. Did the prescriber complete and submit an FDA MedWatch Adverse Event								
	Reporting form?	□ Yes	□ No						
	If YES, please provide a copy of the completed MedWatch form.								
11. Please provide a clinical rationale for the requested medication and address alternatives that have not been									
	may be clinically inappropriate; may include medical record documentation, laboratory results, and/o	or other sup	porting						
	medical documentation (omission of information indicates N/A or none):		·						
	PLEASE NOTE: If prescribing more than the program quantity limit (listed on page 3), please complete a	nd sign pag	e 3*						
PI	lease certify the following by signing and dating below:								
I certify that I have been authorized to request prior review and certification for the above requested service(s). I further certify the my patient's medical records accurately reflect the information provided. I understand that Blue Cross NC may request medical									
re	cords for this patient at any time in order to verify this information. I further understand that if Blue Cross NC det	lermines this	:						
	formation is not reflected in my patient's medical records, Blue Cross NC may request a refund of any payments								
pυ	ursue any other remedies available.								
Pr	rescriber's Signature (Required): Date:								

For Blue Cross NC members, fax form to 1-800-795-9403

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.

DATE: March 2025 Page 2



COMPLETE PAGE 3 ONLY IF REQUESTING A QUANTITY LIMIT EXCEPTION FOR PROSTATE CANCER AGENTS

PRESCRIBER NAME	PRESCRIBER NI	PI [REQUIRED]	Blue Cross NC PROV ID # / TA	X ID [out of state]	
CONTACT PERSON	PRESCRIBE	PRESCRIBER PHONE		PRESCRIBER FAX	
PRESCRIBER ADDRESS	CITY	STATE	ZIP		
PATIENT NAME	Blue Cross NC	ID	DATE OF BIRTH	GENDER	
				M F	
FOR COVERAGE OVER TO PLEASE ANSWER THE FO Please note: This medication of submitting a request for a quar and/or approved (pages 1-2). Associated generic formulation	OLLOWING: requires a prior authorizationtity level override, please e Otherwise, this request will	on before a quar ensure that a pri	ntity limit override can be cor or approval authorization ha	nsidered. Before as been submitte	
Diagnosis Code:					
Med	lication	Quantif	ty per Day (unless specifi	ied)	
Abirtega (abiraterone) 2			4 tablets		
Zytiga (abiraterone) 25			4 tablets		
Zytiga (abiraterone) 50			2 tablets		
Yonsa (abiraterone) 12	<u> </u>		4 tablets		
Xtandi (enzalutamide) 4			4 capsules		
Xtandi (enzalutamide) 4			4 tablets		
Xtandi (enzalutamide) 8			2 tablets		
Nubeqa (darolutamide)			4 tablets		
Erleada (apalutamide)			4 tablets		
Erleada (apalutamide)	240 mg tablet		1 tablet		
ledication Name and Strer	_				
Requested Quantity per day ***Please enter quantity as a num	y: neric value with one decimal pl	_ lace (ex. 1.0. 1.5)	***		
n the space provided, ple nclude documented clinical					
Please certify the followin I certify that I have been authoriz my patient's medical records acc records for this patient at any tim information is not reflected in my pursue any other remedies availa	zed to request prior review and curately reflect the information ne in order to verify this informaty patient's medical records, Blu	I certification for the provided. I under ation. I further un	rstand that Blue Cross NC may derstand that if Blue Cross NC	request medical determines this	
Proscribor's Signature (Re			Dato:		

For Blue Cross NC members, fax form to 1-800-795-9403

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.

DATE: March 2025 Page 3